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Traumatic brain injury causes diffuse axonal injury and loss of cortical neurons. These features are well recognized histologi-
cally, but their in vivo monitoring remains challenging. In vivo cortical microdialysis samples the extracellular ﬂuid adjacent to
neurons and axons. Here, we describe a novel neuronal proteolytic pathway and demonstrate the exclusive neuro-axonal
expression of Pavlov’s enterokinase. Enterokinase is membrane bound and cleaves the neuroﬁlament heavy chain at positions
476 and 986. Using a 100kDa microdialysis cut-off membrane the two proteolytic breakdown products, extracellular ﬂuid
neuroﬁlament heavy chains NfH476 986 and NfH476 1026, can be quantiﬁed with a relative recovery of 20%. In a prospective
clinical in vivo study, we included 10 patients with traumatic brain injury with a median Glasgow Coma Score of 9, providing
640 cortical extracellular ﬂuid samples for longitudinal data analysis. Following high-velocity impact traumatic brain injury,
microdialysate extracellular ﬂuid neuroﬁlament heavy chain levels were signiﬁcantly higher (6.18   2.94ng/ml) and detectable
for longer (44 days) compared with traumatic brain injury secondary to falls (0.84   1.77ng/ml, 52 days). During the initial
16h following traumatic brain injury, strong correlations were found between extracellular ﬂuid neuroﬁlament heavy chain
levels and physiological parameters (systemic blood pressure, anaerobic cerebral metabolism, excessive brain tissue oxygen-
ation, elevated brain temperature). Finally, extracellular ﬂuid neuroﬁlament heavy chain levels were of prognostic value, pre-
dicting mortality with an odds ratio of 7.68 (conﬁdence interval 2.15–27.46, P = 0.001). In conclusion, this study describes the
discovery of Pavlov’s enterokinase in the human brain, a novel neuronal proteolytic pathway that gives rise to speciﬁc protein
biomarkers (NfH476 986 and NfH476 1026) applicable to in vivo monitoring of diffuse axonal injury and neuronal loss in traumatic
brain injury.
Keywords: extracellular ﬂuid; interstitial ﬂuid; neurocritical care; neurodegeneration; neuroﬁlaments
Abbreviations: GCS = Glasgow Coma Score; GOS = Glasgow Outcome Score; NfH = neuroﬁlament heavy chain;
NfL = neuroﬁlament light chain; NfM = neuroﬁlament medium chain
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Traumatic brain injury is a major cause of death and one of the
most frequent neurological disorders. An estimated 1.4 million US
individuals suffer from traumatic brain injury per year (Langlois
et al., 2006a). Mortality is higher with road trafﬁc accidents
(27–34%) compared with falls (10–11%) (Adekoya and
Majumder, 2004). Following road trafﬁc accidents, ﬁre-arm
injury and assault are the other two main causes for severe trau-
matic brain injury (Langlois et al., 2006b; Minino et al., 2006).
High-velocity impact injuries of any type are of particular concern
(Kirkpatrick, 1983; Suneson et al., 1990; Gieron et al., 1998;
Corbo and Tripathi, 2004; Bakir et al., 2005; Walilko et al.,
2005). Neurological morbidity results predominantly from cogni-
tive and behavioural problems causing a reduced quality of life
due to loss of independence and productivity (Dikmen et al.,
1995). Neuroaxonal degeneration is a likely cause for morbidity
and mortality after traumatic brain injury, but is difﬁcult to monitor
in the living human subject (Povlishock, 1992; Smith, 2003).
In their seminal paper, Gennarelli et al. (1982) show that rota-
tional accelerations are the main contributor to diffuse axonal
injury in a primate model. Additionally, driver-dummy data from
vehicle impact testing suggest that rotational accelerations contrib-
ute to over 80% of the brain strain independent of crash mode
(Zhang et al., 2006). These data are in line with neuropathological
studies in humans showing substantial loss of neurons in the sub-
cortical grey matter following traumatic brain injury (Graham
et al., 1992, 2005). Consistent with the post-mortem observations
is experimental work showing that traumatic brain injury causes
diffuse, widespread neuronal damage in addition to focal brain
injury. Hall et al. (2005) demonstrated in a mouse model that
neurodegeneration affected all layers of the ipsilateral cortex,
starting within 6h after impact. Diffuse degeneration affected
neurons in the hippocampus and thalamus (layer CA1, CA3) and
their connections (efferent CA1 pyramidal axons, mossy ﬁbres,
Schaffer collaterals and the perforant path), as well as the
corpus callosum and visual cortex (Hall et al., 2005). The onset
of cytoskeletal degradation after experimental traumatic impact
was found to be as fast as 30min (Deng et al., 2007). The ﬁnal
common pathway results in cellular calcium overload that activates
the enzyme calpain, causing intracellular proteolysis (Deng et al.,
2007; McGinn et al., 2009). Following this enzymatically mediated
degradation, the cytoskeletal proteins and their breakdown prod-
ucts are released into the extracellular ﬂuid. Among these is a
group of proteins known as neuroﬁlaments, which are highly spe-
ciﬁc for the neuroaxonal compartment (Shaw, 1998; Buki and
Povlishock, 2006; Petzold, 2007). In the CNS, neuroﬁlaments are
made up of four subunits, a light (68kDa), medium (150kDa) and
heavy (190–210kDa) chain alongside a-internexin (Shaw, 1998;
Petzold, 2005).
In this study, we show for the ﬁrst time that a speciﬁc biomark-
er for neuronal–axonal degeneration (Shaw, 1998; Petzold, 2007)
can be quantiﬁed in vivo from the human cortical extracellular
ﬂuid (Vespa et al., 2005; Tisdall and Smith, 2006). In a proof of
principle study, we tested whether levels of this protein biomarker
are related to (i) the in vitro neuronal count; (ii) in vitro
characteristics of the microdialysis system; (iii) the phenotype
in vivo (Gennarelli et al., 1982; Kirkpatrick, 1983; Suneson
et al., 1990; Gieron et al., 1998; Corbo and Tripathi, 2004;
Bakir et al., 2005; Walilko et al., 2005; Zhang et al., 2006); (iv)
brain imaging (Marshall et al., 1992; Steyerberg et al., 2008); (v)
other in vivo markers associated with neuroaxonal degeneration
(Buki and Povlishock, 2006) and (vi) prognosis in traumatic brain
injury.
Materials and methods
Patients
Patients suffering from a traumatic brain injury who were admitted to
the Neurosurgical Intensive Care Unit at the National Hospital for
Neurology and Neurosurgery were recruited between January 2006
and February 2007. Inclusion criteria were (i) traumatic brain injury;
(ii) age 516 years; (iii) requirement for intra-cranial pressure monitor-
ing in accordance with published guidelines [(PMID: 10937893) 2000]
and (iv) that written, informed, witnessed consent could be obtained
from the next of kin. Exclusion criteria included (i) polytrauma;
(ii) signiﬁcant thoracic or abdominal injuries; (iii) documented
pre-admission hypotensive (systolic blood pressure 590mmHg) or
(iv) hypoxic (peripheral oximetry saturation 590%) episodes.
High-velocity impact traumatic brain injury was deﬁned based on
mechanism of injury (road trafﬁc accidents, ﬁre-arm, and assault)
(Kirkpatrick, 1983; Adekoya and Majumder, 2004; Walilko et al.,
2005; Langlois et al., 2006b; Minino et al., 2006). Severity of injury
was additionally classiﬁed clinically based on the admission Glasgow
Coma Score (GCS) into mild (GCS 13–15), moderate (GCS 9–12) and
severe (GCS 48).
Brain imaging
All patients underwent computerized tomography (CT). The CT brain
imaging was classiﬁed according to the Marshall criteria (Marshall
et al., 1992; Steyerberg et al., 2008), the presence of traumatic sub-
arachnoid blood (Steyerberg et al., 2008) or an extradural haematoma
(Steyerberg et al., 2008).
Procedures and sample collection
The microdialysis catheter (100kDa molecular weight cut-off, CMA71,
20mm length, 0.6mm diameter polyamide membrane) was implanted
through a triple lumen intra-cranial bolt (Technicam Ltd, Newton,
Abbott, UK) in pericontusional tissue (in cases of contusion injury) or
into the right frontal cortex (in cases of diffuse axonal injury) in agree-
ment with consensus guidelines (Bellander et al., 2004). The catheter
was perfused with commercially available artiﬁcial CSF (NaCl 147mM,
KCl 2.7mM, CaCl 1.2mM, MgCl 0.85mM as supplied by CMA). The
catheter was perfused at a constant ﬂow rate of 0.3ml/min. The
system was allowed to equilibrate for 1h prior to starting sample
collection as per consensus guidelines (Bellander et al., 2004).
Samples were collected on an hourly basis and frozen within 10min
of collection. The position of the gold labelled probes was veriﬁed
on subsequent CT scans (except in Patient 5 were the catheter was
inserted very late and Patient 9 were the catheter was removed very
early). Intra-cranial pressure (Codman microsensor, Randolph,
Ma, USA), brain temperature and calibrated brain tissue
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LICOX device (Integra LifeSciences Corporation). Hourly mean values
for these variables were calculated and conﬁrmed by one physician
(M.T.).
Cortical brain tissue samples
Post-mortem cortical tissue from traumatic brain injury cases (n =4 )
were taken from areas close to macroscopically visible contusions.
Control cortical post-mortem tissue was taken from two patients
who died of a non-neurological condition. In addition, control brain
tissue samples were collected from patients undergoing surgery for
intractable epilepsy (n = 3). Tissue samples were ﬁxed with formalin
prior to embedding in parafﬁn.
Patient management
Patients were sedated with propofol and fentanyl and received
protocol-guided stepwise therapy based on the Brain Trauma
Foundation guidance (Kitson, 2005) to maintain a cerebral perfusion
pressure above 60mmHg. As part of the intra-cranial pressure man-
agement, patients were mechanically ventilated to maintain a CO2
partial pressure of 4.0–4.5kPa. Blood glucose was maintained between
4.0 and 9.0mM using an insulin (i.v. actrapid) sliding scale.
Management of the patients was not affected by involvement in the
study.
Outcome measure
Two clinical endpoints were collected: (i) survival on discharge from
hospital and (ii) the Glasgow Outcome Score (GOS) at 3 months and
6 months after injury. The GOS was dichotomized into unfavourable
recovery (GOS: 1 indicates death; 2, persistent vegetative state and 3,
severe disability) or favourable recovery (GOS: 4 indicates moderate
disability; 5, good recovery) (Teasdale et al., 1998).
Sample analysis
In each patient, the microdialysis probe was allowed to stabilize for 1h
(Bellander et al., 2004). Only samples collected after this equilibration
period were investigated. At the end of each 1h collection period, the
microdialysate of the extracellular ﬂuid was immediately analysed for
lactate and pyruvate with the bedside CMA 600 Analyser (CMA
Microdialysis) using an enzymatic colourimetric technique (Aﬁnowi
et al., 2009). For quality control analysis, artiﬁcial CSF samples were
analysed on a calibrated YSI 2003 STAT Plus Glucose and Lactate
Analyser (YSI Inc., Yellow Springs, Ohio, USA) and compared with
the values derived by the CMA 600 Analyser. The batch-frozen sam-
ples were pooled in 3h intervals and extracellular ﬂuid neuroﬁlament
heavy chain (NfH) levels were measured using an in-house developed
and externally validated enzyme-linked immunosorbent assay (Petzold
et al., 2003; Petzold and Shaw, 2007). All samples were analysed in
duplicates and repeated if the coefﬁcient of variation was greater than
the intra-assay precision of 10% (Petzold et al., 2003). The analyst
was blinded to all other information.
Recovery
Recovery experiments were carried out as previously described
(Aﬁnowi et al., 2009). Large volume (100ml) CSF samples (n = 12)
were used as source solutions. Microdialysis pumps (CMA 106; CMA
Microdialysis AB, Solna, Sweden) were used at a constant ﬂow rate of
0.3ml/min. The in vitro relative recovery was calculated as:
Relative recovery ð%Þ¼dialysate concentration :
reference solution concentration   100:
Gel electrophoresis
Following the NfH enzyme-linked immunosorbent assay, surplus of the
extracellular ﬂuid samples was kept at 4 C. Extracellular ﬂuid samples
with high NfH content were pooled. Due to the small remaining
sample size after performing the enzyme-linked immunosorbent
assay, a total of 84 microvials from ﬁve patients were pooled to
give 250ml of extracellular ﬂuid, known to have a high NfH concen-
tration. The pooled extracellular ﬂuid was mixed with 170ml lithium
dodecyl sulphate, 10ml dithiothreitol and heated at 65 C to unfold the
proteins. The sample (400ml) was loaded onto the 4–12% Bis–Tris and
3–8% Tris–acetate gels. Molecular weight markers (Invitrogen,
MagicMark, Western Standard and SeeBlue Plus2, Invitrogen) were
used for each run. The gels were run under reducing conditions
(Invitrogen System, PowerEase 500, 200V, 120mA, 25W).
Immunoblot
The proteins were transferred from the gel to a nitrocellulose mem-
brane over a 2h blotting period (25V, 160mA, 17W). The membrane
was blocked in 2% fat milk powder/0.9% saline for 1h. Blocking
solution was decanted and the membrane was washed ﬁve times for
3min with washing solution (0.1% fat milk powder/0.9% saline,
0.1% Tween-20). The membranes were either incubated with the
ﬁrst antibody in a single well or adjusted between two plastic layers
and sealed in a manifold (Hoefer) so that each of the 10 channels
overlaid the entire area onto which the proteins have been transferred.
The channels were each ﬁlled with 3ml of 0.1% fat milk powder/
0.9% saline, containing antibodies different antibodies in a 1:1000
dilution. For detection of NfH, six mouse monoclonal antibodies dir-
ected at different phosphoepitopes (see Table 1 in Petzold et al.,
2003) were used: SMI 32, SMI 34, SMI 35, SMI 37, SMI 38 and
SMI 311 (originally purchased from Sternberger Monoclonals
Incorporated, now Covance Research Products, Berkeley CA, USA).
In addition, antibodies to the neuroﬁlament light chain (NfL) and
medium chain (NfM) were also used (NR4 mouse monoclonal
anti-NfL from Sigma and rabbit polyclonal anti-NfM from Afﬁnity,
UK). Antibodies were incubated at 4 C overnight on a shaker. After
decanting the antibodies, each channel was washed ﬁve times for
3min with washing solution. The channels were then ﬁlled with the
appropriate horseradish peroxidase-labelled detector antibody (swine
anti-rabbit or rabbit anti-mouse, both Sigma) and incubated for 1h at
room temperature. Antibodies were decanted and the membranes
were washed in each channel for 5min, 10 times. The membranes
were incubated with the chemiluminescence substrate (SuperSingal
West Pico, Thermo Scientiﬁc, #34078) for 5min. The dried membranes
were visualized on an AlphaEase FluorChem SP CCD camera.
Dephosphorylation and proteolysis
HPLC-puriﬁed bovine NfH was diluted into glycine buffer (pH 10.4) at
a concentration of 50mg/ml. NfH was dephosphorylated with 100mU
of alkaline phosphatase (ALP, EC 3.1.3.1, Sigma, P4252) at 37 C for
1h (Petzold et al., 2008). Aliquots of phosphorylated NfH and depho-
sphorylated NfH were incubated with (i) enterokinase (EC 3.4.21.9,
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3.4.21.1, Sigma, C-4129).
Laser capture microdissection
PC6-3 cells, a derivate from the PC12 cell line, were converted into
neuronal-like cells as described by Pittman et al. (1993). The cells were
grown in Roswell Park Memorial Institute medium, 10% horse serum,
5% foetal calf serum and penicillin/streptomycin. For differentiation,
the cells were switched to Roswell Park Memorial Institute medium,
2% horse serum, 1% foetal calf serum + 100ng/ml nerve growth
factor. The cells were then mounted on polyethylene naphthalate
membrane-covered glass slides. The cells were washed three times
with phosphate buffered saline and ﬁxed in 70% ethanol. The cells
were air dried and the Laser Microbeam System (P.A.L.M., Microlaser
Technologies AG, Munich, Germany) was used under visual control to
capture the cells in barbitone buffer (pH 8.9) used for enzyme-linked
immunosorbent assay (Schutze et al., 2007).
Protein extraction from snap frozen
brain tissue
Protein extraction was modiﬁed from the method previously
described (Ericsson et al., 2007). Lithium dodecyl sulphate was
added to the samples at 50 times the dry weight of the frozen brain
tissue samples. All samples were sonicated on ice in a polypropylene
tube. Samples were then incubated at 70 C for 10min. After rigorous
mixing at 1400rpm samples were centrifuged at 13.2   10g for
10min at 4 C. The supernatant was used for western and
immunoblotting.
Immunohistochemistry
Sections (7mm) were dewaxed and rehydrated followed by 15min
incubation in 3% hydrogen peroxide and deionized water followed
by microwave heat treatment. Protein blocking was carried out with
normal horse serum. Sections were incubated overnight at room tem-
perature with anti-goat enterokinase antibody (1:300 Santa Cruz
Biotechnology, Inc., CA 95060, USA) using Vector ImmPRESS
TM anti
goat detection system kit (Vector Labs: Burlington, CA, USA) and
visualized with diaminobenzidine chromogen. Sections were washed
with phosphate buffered saline + 0.05% Tween-20 in each step.
Control sections were treated the same but the primary antibody
was omitted. Neuronal apoptosis was assessed by staining for
caspase-3 (1:500, Clone 269518, Code MAB 835, R&D System,
Minneapolis, USA) as described (Sulejczak et al., 2008; Sairanen
et al., 2009; Umschwief et al., 2010).
Immunoﬂuorescence
The same procedure was used as that for immunohistochemistry up
until the incubation of the antibodies. Sections were incubated with
enterokinase antibody ﬁrst at 1:400 dilution followed by secondary
ImPRESS anti-goat then Fluorescein Green Tyramide Signal
Ampliﬁcation (PerkinElmer Life and Analytical Sciences, Boston, MA,
USA). After washing, the sections were quenched with 1% hydrogen
peroxide for 15min in order to prevent any deposited tyramide com-
bining with the second tyramide signal that followed. After washing,
protein blocking was done with normal horse serum (Vector labora-
tories) followed by incubation with primary monoclonal antibody
SMI32 (1:500, Covance, Emeryville, CA, USA) and monoclonal neu-
roﬁlament 200 (NE14, 1:3000, Sigma, St Louis, Missouri 63103, USA).
Sections were incubated with relevant secondary horseradish peroxid-
ase detection system followed by CY3 from the Tyramide Signal
Ampliﬁcation Kit. Sections were mounted on Vectashield with Dapi
(Vector laboratories) and visualized with a Leica confocal laser micro-
scope. After each step sections were washed with phosphate buffered
saline. Negative controls were treated the same except the primary
antibodies were omitted.
Data analysis
Statistical analyses were performed using SAS software (V9.2).
Independent variables were compared using the non-parametric two-
sample exact Wilcoxon rank-sum test for two variables and a two-way
unbalanced ANOVA (general linear model) for more than two variables.
Repeated measurement analysis was performed on 3h epochs
(pooled extracellular ﬂuid sampling time) using mixed models. The
best ﬁtting model was selected based on the best ﬁtting covariance
structure (Littell et al., 1998). The linear relationship between
continuous variables was evaluated using the Spearman correlation
coefﬁcient. The level of signiﬁcance for the multiple correlations was
corrected using the Bonferroni method. The Chi-Square-test and
Fisher’s exact test were used for comparing proportion of patients.
Two-tailed tests were used throughout and P-values of 50.05 were
accepted as signiﬁcant.
Table 1 Neuronal apoptosis in traumatic brain injury
ID Age (gender) Tissue Brain area Condition Caspase-3
Patient 1 85 (F) Post-mortem Contusion, SDH, ICH Traumatic brain injury +
Patient 2 73 (F) Post-mortem Contusion Traumatic brain injury +
Patient 3 83 (M) Post-mortem Contusion Traumatic brain injury +
Patient 4 51 (M) Post-mortem Contusion Traumatic brain injury +
Patient 5 39 (F) Post-mortem Temporal lobe Normal control  
Patient 6 35 (F) Post-mortem Temporal lobe Normal control  
Patient 7 48 (M) Surgery Temporal lobe Epilepsy  
Patient 8 34 (M) Surgery Temporal lobe Epilepsy  
Patient 9 47 (F) Surgery Temporal lobe Epilepsy  
Neuronal staining for caspase-3:   = absent,   = uncertain, + = positive. ICH = intra-cranial haemorrhage; SDH = subdural haematoma.
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Neuroﬁlaments are a protein biomarker
for neuronal loss
As a proof of principle, an in vitro cell culture set-up was used to
investigate the relationship between the NfH protein concentration
and the number of PC12 cells (Fig. 1A). Individual PC12 cells were
collected using laser-capture microdissection (Schutze et al.,
2007). A minimum of 50 PC12 cells were needed for detection
of NfH in the enzyme-linked immunosorbent assay (Petzold et al.,
2003). The linear relationship (R = 0.98, P = 0.013) of
laser-captured PC12 cells with NfH levels equated to: PC12 cells
number = 1245   NfH–46 (Fig. 1B). In PC12 cells, NfH accounted
only to 0.011% of the total soluble cellular protein fraction which
was 24.6 times 50.271% quantiﬁed from human grey matter
(P = 0.0014, Fig. 1C).
The relative recovery of NfH from a solute is inﬂuenced by the
pore size of the microdialysis membrane (Fig. 1E). The in vitro
recovery experiment showed a signiﬁcant loss of NfH from the
source solute compared with samples recovered either through a
20 or 100kDa microdialysis membrane [general linear model,
F(2,33) = 171, P50.0001, Fig. 1F]. The mean relative recovery
of NfH for the 100kDa membrane (CMA71, 20mm length,
0.6mm diameter polyamide membrane) was 20.7   3.2
(Fig. 1G). For the 20kDa membrane (CMA70, 20mm length,
0.6mm diameter polyamide membrane) the relative recovery
Figure 1 Neuroﬁlaments are a protein biomarker for neuronal loss. (A) The cytoskeleton of the neuron and axon contains the neuro-
ﬁlament heavy chain (NfH, ﬁlled red boxes). The number of laser-captured neurons/axons relates to the NfH levels quantiﬁed by
enzyme-linked immunosorbent assay. (B) The estimated quantitative relationship between the number of laser-captured PC12 cells and
the NfH concentration is expressed as: (number of PC12 cells  1245   NfH   46, R = 0.98, P = 0.013). The lowest number of
laser-captured cells giving for quantiﬁable NfH levels was 50 (data not shown). (C) The percentage of NfH to total soluble protein is 24.6
times higher in the human grey matter compared with PC12 cells. (D) In the injured human brain, NfH is released from the neuronal
compartment into the extracellular ﬂuid (ECF, dark grey box). Placement of a microdialysis catheter into the human cortex, adjacent to
neurons, allows recovery of NfH from the human extracellular ﬂuid. (E) The in vitro recovery experiment showed that NfH could be
recovered from a source solute using a 100kDa microdialysis catheter, but not a 20kDa catheter. (F) Consequently, the relative recovery
of NfH was negligible for the 20kDa catheter and 20% for the 100kDa microdialysis catheter.
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2 = 18.23,
P50.0001).
Neuroﬁlament heavy chain cleavage
products are recovered from human
extracellular ﬂuid
Pooled human extracellular ﬂuid with high and low NfH levels
were used to investigate how this large protein (1020 amino
acids corresponding to a molecular mass of 113kDa) could be
recovered through a 100kDa catheter membrane. Of note, most
of the literature refers to the molecular mass derived from sodium
dodecyl sulphate gels which is in the 190–210kDa range. The
difference between these molecular weight values is explained
by altered electrophoretic mobility caused by the charge/weight
of the bound phosphate (Petzold, 2005). Using gel electrophoresis
we demonstrated that high molecular weight proteins were pre-
sent in extracellular ﬂuid with high NfH levels but not in extracel-
lular ﬂuid with low NfH levels (Fig. 2A). The immunoblot showed
immunoreactivity of a protein with SMI34 (Fig. 2B). The immu-
noreactivity appears to be speciﬁc for the NfH phosphoforms
SMI32, SMI38, SMI34, SMI35, SMI37 and SMI311, as there
was no cross-reactivity with antibodies against NfM and NfL
(Fig. 2C). Comparative immunoblotting shows identiﬁes two NfH
cleavage products in the 100–120kDa range (Fig. 2D, Lane 2 and
Fig. 2E, Lanes 2 and 7).
The described in vivo cleavage products can be reproduced
in vitro by incubation of puriﬁed NfH with enterokinase
(Fig. 2D, Lane 4 and Fig. 2E, Lane 8). The electrophoretic mobility
of the extracellular ﬂuid NfH cleavage products (NfH476 986 and
NfH476 1026) matches what can be expected from the known NfH
enterokinase cleavage sites (Fig. 2F). The corresponding molecular
weight of NfH476 986 and NfH476 1026 calculated from the amino
acid sequence of the cleavage product corresponds to 56–60kDa
(Fig. 2F). In this article, the extracellular ﬂuid NfH cleavage prod-
ucts will be referred to as extracellular ﬂuid NfH.
A novel neuronal proteolytic pathway
The immunohistochemistry shows the presence of enterokinase in
the frontal cortex of a patient with traumatic brain injury (Fig. 3A).
Mainly large neurons and their axons are stained. There was
almost no immunoreactivity to enterokinase in the deep white
matter (data not shown). Enterokinase was not found in endothe-
lial cells, astrocytes or microglia. The exclusively neuronal expres-
sion of enterokinase is not speciﬁc for traumatic brain injury
because a similar staining pattern is also seen in patients with
epilepsy (Fig. 3B). The immunohistochemistry suggests that the
heavy subunit of enterokinase may be membrane bound. This
observation is conﬁrmed by the immunoﬂuorescence (Fig. 3C
and D). The predominant expression of the enterokinase heavy
chain in the human cortex, but not deep white matter, is con-
ﬁrmed by immunoblotting (Fig. 3E). In a subpopulation of large
neurons, enterokinase colocalizes with phosphorylated NfH
(Fig. 3C).
Apoptosis of cortical neurons in
traumatic brain injury
In all traumatic brain injury post-mortem cases there are apoptotic
caspase-3 positive cells in the vicinity of the contusion (Table 1).
Staining for caspase-3 was essentially absent from normal control
post-mortem tissue and temporal lobar tissue removed during epi-
lepsy surgery (Table 1). The morphological analysis of the
caspase-3 cells identiﬁes different types of neurons including pyr-
amidal cells (Fig. 4A and B). Many of the caspase-3 positive cells
were degenerate and apoptotic.
Patients
The clinical characteristics of the 10 patients with traumatic brain
injury recruited into this prospective, longitudinal study are sum-
marized in Table 2. Nine patients were male and one was female.
The median age was 39 years (range 20–68 years). The severity of
the injury ranged from mild to severe with a median admission
GCS of 9 (range 4–15). The individual CT brain scans document-
ing the brain pathology and the position of the microdialysis cath-
eter are shown in Fig. 5.
Extracellular ﬂuid neuroﬁlament heavy
chain in traumatic brain injury
A total of 640 microdialysis samples were collected on an hourly
basis for this study. The median time between injury and catheter
insertion was 14h (range 7–37h) when considering all but one
patient (Patient 5) who was referred to us with a 5day delay.
The individual extracellular ﬂuid NfH levels are shown in Fig. 5.
An early peak of the extracellular ﬂuid NfH concentration was
observed in 7/10 (70%) of patients (Patients 1, 3, 4, 6, 7, 8
and 9; indicated by single arrows in Fig. 5). In addition, secondary
peaks of extracellular ﬂuid NfH were observed in eight patients
(Patients 1, 2, 3, 4, 5, 6, 7 and 10; indicated by double arrows in
Fig. 5). In four patients the concentration of extracellular ﬂuid NfH
measured in secondary peaks during the later disease course ex-
ceeded what was observed initially (Patients 2, 3, 7 and 10). Due
to small sample volume in Patient 5, it was only possible to meas-
ure extracellular ﬂuid NfH 25h after catheter insertion. Patient 5
showed an early peak of extracellular ﬂuid NfH at  0.4ng/ml.
The longitudinal data on extracellular ﬂuid lactate and extracellular
ﬂuid pyruvate values in this patient, directly following catheter
insertion, suggest that this extracellular ﬂuid NfH peak was not
likely to be a consequence of a catheter insertion artefact
(Supplementary Fig. 1).
Phenotypic analyses
We classiﬁed road trafﬁc accidents in three patients and assault in
one patient (Patient 5) as high-velocity impact traumatic brain
injury. However, the actual impact of injury was not recorded
(see below). A fall was the cause of traumatic brain injury in the
remaining six patients (Table 2). Patients who suffered from
high-velocity impact traumatic brain injury had considerably
higher early extracellular ﬂuid NfH levels compared with those
Enterokinase neuroﬁlament cleavage in the brain Brain 2011: 134; 464–483 | 469Figure 2 Identiﬁcation of ﬁve new NfH enterokinase cleavage products. (A) Gel electrophoresis of pooled extracellular ﬂuid (ECF)
(4–12% Bis-Tris gel, Coomassie stain). There are a number of distinct bands visible between 98 and 188kDa in extracellular ﬂuid pooled
(100kDa catheter) from samples with high NfH, which can not be visualized from the extracellular ﬂuid of samples with non-measurable
NfH. (B) The immunoblot shows a  100kDa protein recognized by SMI34 in the extracellular ﬂuid pooled from samples with a high NfH
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(continued)suffering from a fall. The averaged extracellular ﬂuid NfH levels
over the initial 24h were 7-fold higher (6.18   2.94ng/ml) fol-
lowing high-velocity impact traumatic brain injury compared with
a fall (0.84   1.77ng/ml). Moreover, extracellular ﬂuid NfH levels
remained for longer on a high level following high-velocity impact
traumatic brain injury [F(19,344) = 28.72, P50.0001, Fig. 6A].
Following a fall, the extracellular ﬂuid NfH levels declined steadily
to become non-detectable after an average of 2 days.
In patients with a high-velocity impact traumatic brain injury,
the extracellular ﬂuid lactate to pyruvate ratio was above 25 at
onset and the longitudinal proﬁle was different compared with the
lactate to pyruvate ratio in traumatic brain injury after fall
[F(18,366) = 3.67, P50.0001, Fig. 6B]. Similarly, there was a
mild but signiﬁcant difference in the brain temperature proﬁle
[F(18,297) = 5.89, P50.0001, Fig. 6D]. Finally, the intra-cranial
pressure remained higher in patients with traumatic brain
injury with a fall compared with high-velocity impact traumatic
brain injury throughout the entire observation period
[F(18,370) = 1.94, P = 0.012, Fig. 6G]. None of the other physio-
logical parameters distinguished between the two groups (Fig. 6C,
E, F and H).
Because the impact of injury was not recorded, additional ana-
lyses were performed comparing three categories: road trafﬁc ac-
cidents, assault and falls. There was a signiﬁcant overall difference
between these three groups over time for extracellular ﬂuid NfH
levels (F = 3.41, P = 0.0049) and brain temperature (F = 8.13,
P50.0001). However, signiﬁcance was lost for the extracellular
ﬂuid lactate to pyruvate ratio (F = 0.35, P = 0.91) and intra-cranial
pressure (F = 0.50, P = 0.81).
Injury severity was classiﬁed according to the GCS into mild
(n = 3), moderate (n = 2) and severe (n = 5) traumatic brain
injury. There was no signiﬁcant difference for extracellular ﬂuid
NfH levels according to the GCS [F(5,481) = 0.14, P = 0.98].
Brain imaging analyses
There was a signiﬁcant difference in extracellular ﬂuid NfH
levels over time in patients with traumatic brain injury with
traumatic subarachnoid blood (n = 3) compared with those
without traumatic subarachnoid blood [n =7 , F(19,343) = 4.07,
P50.0001].
No such differences were found for patients with traumatic
brain injury with extradural haematoma compared with those
without (data not shown). Likewise, there were no signiﬁcant dif-
ferences for extracellular ﬂuid NfH levels according to the Marshall
CT brain imaging classiﬁcation (Marshall et al., 1992) (data not
shown).
Physiological correlations
A correlation analysis was performed using the multimodal moni-
toring data set focusing on four physiological parameters that
have been related to injury severity and outcome in traumatic
brain injury (Enblad et al., 2001; Hutchinson et al., 2002;
Butcher et al., 2007; Arieli et al., 2008; Belli et al., 2008;
Diringer, 2008; Polderman, 2008; Stiver and Manley, 2008).
Figure 7A shows the statistical strength of the correlation
(Spearman’s R) between these parameters and extracellular ﬂuid
NfH levels.
Lactate to pyruvate ratio
There was a strong and signiﬁcant correlation between the lactate
to pyruvate ratio and extracellular ﬂuid NfH levels in the initial
three epochs (R = 0.83 to R = 0.63, Fig. 7A). The raw data for
the second epoch show that extracellular ﬂuid NfH levels started
to rise with a lactate to pyruvate ratio 420 (Fig. 7B).
Figure 2 Continued
concentration (Lanes 2 and 4) but not from samples with non-measurable NfH levels (Lane 3). No other higher molecular weight NfH
fragments were recovered through the 100kDa microdialysis membrane (3–8% Tris–acetate gel, because of overexposure of the mo-
lecular weight markers (MW), the gain for Lane 1 was digitally reduced). (C) The  100kDa protein fragment is recognized by monoclonal
antibodies against phosphorylated (SMI34, SMI35) and non-phosphorylated (SMI32, SMI38, SMI37, SMI311) NfH epitopes. The
strongest immunoreactivity was observed with SMI34 and SMI38. There was no binding to the detecting rabbit anti-mouse horseradish
peroxidase labelled antibody (RaM-HRP). Equally, there was no binding with monoclonal antibodies against NfL or NfM, known to have
a small degree of cross-reactivity with the NfH head/rod region. This suggests that the recovered protein stems from the NfH tail
region (4–12% Bis-Tris, 1 well gel, antibody incubation in manifold). (D) Immunoreactivity against hyperphosphorylated NfH (SMI34).
The 100–120kDa band from human extracellular ﬂuid (Lane 2) migrates in a similar range to a fraction present in HPLC-puriﬁed bovine
NfH (Lane 3), which can be further enhanced by limited proteolysis with enterokinase (EK, Lane 4) but not a-chymotrypsin (CT, Lane 4).
Not all of the puriﬁed higher molecular weight NfH migrates into the gel (top part of Lanes 3–4). There is no immunoreactivity of SMI34
with dephosphorylated puriﬁed or proteolysed NfH (Lanes 7–9). (E) Immunoreactivity against non-phosphorylated NfH (SMI38). The
100–120kDa band from human extracellular ﬂuid (Lane 2) migrates in the same range as partially enterokinase proteolysed
non-phosphorylated NfH (Lane 8). Enterokinase proteolysis reveals three additional bands ( 90, 40, 20kDa) for both phosphorylated
(Lane 4) and non-phosphorylated NfH (Lane 8). (F) Cleavage of NfH with enterokinase occurs at four sites (ExPASy, peptide cutter),
leaving 12 hypothetical proteolytic fragments, ﬁve of which probably explain the immunoreactivity against SMI38 (Lanes 4 and 8 in E).
Cleavage at position 476 alone (ﬁrst dark grey box) or positions 476 and 986 (second dark grey box) is thought to produce the
polypeptides giving rise to the immunoreactivity against SMI34 and SMI38 seen in the 100–120kDa range (Lanes 1 and 3 in D, Lanes 1
and 8 in E). The immunoreactivity of the phosphorylated NfH 35–39kDa and 25–28kDa fragments (bottom two light grey boxes) with the
non-phosphoepitope speciﬁc monoclonal antibody SMI38 (Lane 4 in E) may be explained by structure related dephosphorylation of a
serine residue (e.g. at position 865), adjacent to the enterokinase cleavage sites or alternatively by limited phosphatase activity of
enterokinase. ALP = alkaline phosphatase.
Enterokinase neuroﬁlament cleavage in the brain Brain 2011: 134; 464–483 | 471Figure 3 Enterokinase is expressed in cortical neurons and axons. (A) Immunohistochemistry demonstrates that cortical neurons and their
axons are selectively stained for enterokinase (frontal lobe, traumatic brain injury). Enterokinase appears to localize to the membrane of
neurons and axons (scale bar = 10mm). (B) A similar staining pattern for enterokinase is seen in control tissue (frontal lobe, epilepsy). This
suggests that enterokinase is expressed in a subset of human cortical neurons and not a speciﬁc phenomenon seen in traumatic brain injury
(scale bar = 10mm). (C) Confocal imaging shows that large neurons positive for enterokinase also stain for phosphorylated NfH in trau-
matic brain injury (scale bar = 10mm). (D) Enterokinase was not found in neurons, which predominantly expressed dephosphorylated NfH
SMI32 in traumatic brain injury (scale bar = 25mm). (E) The immunoblot shows presence of the heavy chain of enterokinase in homo-
genated human cortex (four traumatic brain injury cases, Lanes 4, 6, 8 and 10), but not in adjacent white matter tissue (Lanes 3, 5, 7
and 9). There is a mild degree of cross-reactivity of the antibody (LC13) with the enterokinase light chain, seen for the puriﬁed protein
only (Lane 2,  50kDa). The molecular weight markers are shown in Lane 1.
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The mean arterial blood pressure correlated signiﬁcantly with
extracellular ﬂuid NfH levels between the second and ﬁfth epoch
(R =  0.75 to R =  0.46, Fig. 7A) and during the later course
when cerebral perfusion pressure management became critical
(Fig. 6H). During the epoch where the correlation of the mean
arterial blood pressure with extracellular ﬂuid NfH levels was the
strongest (Epoch 4, R =  0.75, P50.0001), there was also an
inverse correlation of the cerebral perfusion pressure with extra-
cellular ﬂuid NfH levels (R =  0.67, P = 0.0001, Fig. 7A). The raw
data show the highest extracellular ﬂuid NfH levels for a mean
arterial blood pressure below 90mmHg (Fig. 7D).
Brain oxygenation
There was a moderate correlation of the brain tissue oxygenation
with extracellular ﬂuid NfH levels (R = 0.85 to R = 0.73, Fig. 7A).
The raw data for the second epoch show that this correlation was
due to a scatter of high CSF NfH levels for brain tissue oxygen-
ation levels above 30kPa (Fig. 7F).
Brain temperature
There was a signiﬁcant correlation between higher brain tempera-
ture and extracellular ﬂuid NfH levels (R = 0.72 to R = 0.51,
Fig. 7A). The raw data show the highest extracellular ﬂuid NfH
levels for a brain temperature above 37 C (Fig. 7H).
Prognosis
The last hypothesis tested was that extracellular ﬂuid NfH levels
may be of prognostic value in traumatic brain injury (Buki and
Povlishock, 2006; Petzold, 2007). Five (50%) of the 10 patients
Table 2 Patients demographics
ID Age
(gender)
High impact
traumatic
brain
injury
Admission
Eyes Verbal
Motor (GCS)
CT brain imaging Other injury Comorbidity Catheter
position
Time to
death
(days)
GOS
(3 months)
GOS
(6 months)
1 57 (F) + E4V4M6 (14) R temporal fracture,
tSAH, EDH, SDH
Clavicular
fracture
Hypothyroidism R frontal 5 1 1
2 45 (M)   E1V1M1 (5) L SDH, tSAH None None L frontal 6 1 1
3 48 (M)   E4V5M6 (15) frontal fracture,
contusions
None None L frontal 4 1 1
4 32 (M) + — (11) R SDH None None R frontal — 4 4
5 22 (M) + E2V2M6 (10) L parietotemporal
fracture, SDH
None None R frontal — 4 4
6 68 (M)   — (14) R SDH, R ICH,
R contusions
None None R frontal — 2 2
7 44 (M)   E1V1M5 (7) tSAH, contusions None None L frontal 5 1 1
8 27 (M)   E2V2M4 (8) L EDH, tSAH None None R frontal 5 1 1
9 20 (M) + E1V1M5 (7) R temporal fracture,
EDH
None None R frontal — 5 5
10 34 (M)   — (4) L temporal fracture,
L SDH, contusions,
pontine ICH
None None L frontal — 3 3
— = data not available; E = eyes; EDH = extradural haematoma; (F) = female; ICH = intra-cranial haemorrhage; L = left; (M) = male; M = motor; R = right; SDH = subdural
haematoma; tSAH = traumatic subarachnoid haemorrhage, V = verbal.
Figure 4 Apoptosis of cortical neurons in traumatic brain
injury. (A) Caspase-3 positive pyramidal cells in the vicinity of
a cortical contusion from a patient with traumatic brain injury
(cases 18–95). (B) Caspase-3 positive neuronal like cells with
dendritic processes in the vicinity of the contusion area of
another patient with traumatic brain injury. Scale bar = 10mm.
Enterokinase neuroﬁlament cleavage in the brain Brain 2011: 134; 464–483 | 473Figure 5 Extracellular ﬂuid NfH levels in traumatic brain injury. The longitudinal proﬁle of extracellular ﬂuid NfH levels in individual
patients is shown in relation to catheter localization, time from catheter insertion and time from injury. The tip of the catheter is indicated
by a black arrow overlaid to the patients’ CT brain scan. Early extracellular ﬂuid NfH peaks are identiﬁed by single arrows. Secondary
extracellular ﬂuid NfH peaks occurring after a period of decreasing or consistently low extracellular ﬂuid NfH levels are indicated by double
arrows. Note that the scale for the y-axis is individually optimized for best visualization of extracellular ﬂuid NfH levels.
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(continued)with traumatic brain injury died within a median of 5 days (range
4–6 days) following the injury (Table 2).
The individual percentage of hours with pathological values for
the sampled physiological parameters spanning the entire obser-
vation period (up to 230h post-traumatic brain injury) are shown
in Table 3. These physiological parameters were more frequently
pathological in non-survivors compared with survivors for
intra-cranial pressure (P50.0001), lactate to pyruvate ratio
425 (P = 0.0003) or lactate to pyruvate ratio 440
(P50.0001), brain tissue oxygenation (P50.0001) and brain
temperature (P50.0001), but not for the cerebral perfusion pres-
sure (P = 0.84). Non-survivors had signiﬁcantly more periods
where the mean hourly lactate to pyruvate ratio was above our
cut-off of 25 or Vespa’s more conservative cut-off of 40 (Vespa
et al., 2005; Belli et al., 2008) (Table 3).
The initial prognostic value of these physiological parameters
and of extracellular ﬂuid NfH levels were investigated with logistic
regression models using survival as the outcome variable. Models
were tested for validity based on the minimum observation period
needed to reveal any meaningful prognostic information. Table 4
shows that after a 12h observation period, the best predictor for
mortality was extracellular ﬂuid NfH levels with an odds ratio of
7.68 [95% conﬁdence interval (95% CI) 2.15–27.46]. The other
two strong predictors of mortality were the intra-cranial pressure
(5.06, 95% CI 1.84–13.89) and admission GCS (4.13, 95% CI
1.72–9.94).
Discussion
In this translational, proof of principle study, we describe a speciﬁc
biomarker (extracellular ﬂuid NfH) related to a novel neuronal
proteolytic pathway involving Pavlov’s enterokinase (Ivan P.
Pavlov, Russian neurologist, 1849–1936). Quantiﬁcation of the
enterokinase cleavage products neuroﬁlament heavy chain
(NfH476 986 and NfH476 1026) from the human extracellular
ﬂuid allowed for in vivo monitoring of neuronal loss in traumatic
brain injury. The two discovered protein fragments are different to
the 53kDa and 57kDa breakdown products with NfL immunor-
eactivity shown to appear  3h following traumatic brain injury
in vivo and in vitro (Nixon and Sihag, 1991; Posmantur et al.,
1998, 1994). The molecular weight of the observed NfH break-
down products is also less than the previously described 120 and
146kDa fragments following calpain induced proteolysis
(Greenwood et al., 1993), bearing in mind that these molecular
weight data were based on electrophoretic mobility. This observa-
tion led to the discovery of enterokinase as the responsible pro-
teolytic enzyme. The known consensus for enterokinase cleavage
site, DDDDK (Boulware and Daugherty, 2006), is very similar to
the cleavage sites found in NfH in our study, which are either
EEEK or EEEEK. The presence of enterokinase in the human
brain has not previously been reported. Enterokinase was originally
discovered from the succus entericus of the dog (Schepowalnikow,
1899; Pavlov, 1910). Probably interested in intestinal movements
Figure 5 Continued.
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acquired reﬂex), they named the enzyme enterokinase, a mis-
nomer that is still widely used. In fact, the enzyme is a serine
protease also known as enteropeptidase (Light and Janska,
1989). While our discovery is novel, it is perhaps not entirely
surprising as the presence of other serine proteases that should
depend on activation by enterokinase, such as trypsin, have been
described in the brain (Wiegand et al., 1993; Blaber et al., 2002).
Interestingly, co-compartmentalization of enterokinase with key
modulators of the extracellular matrix (matrix metalloprotease-9,
trypsin-2) has been reported in systemic carcinoma (Vilen et al.,
2008). Future studies are needed to investigate whether enteroki-
nase also plays a role in modulation of the extracellular matrix of
the brain and thus in plasticity. The membrane bound
colocalization of enterokinase with phosphorylated NfH may also
indicate a role for neuronal reshaping during neuronal plasticity or
for activation pathways of other brain proteases relevant to
Alzheimer’s disease (Leissring, 2008), immune-mediated demyelin-
ation (Blaber et al., 2002) and traumatic brain injury (Buki and
Povlishock, 2006).
This serendipitous discovery aside, the results of our ﬁrst two
research hypotheses were instructive. In a proof of principle ap-
proach, we were able to show a linear relationship between
number of laser-captured PC12 cells and NfH levels measured. A
limitation of this approach, for methodological reasons, is that this
cell line is known to express low levels of less phosphorylated NfH
(Lindenbaum et al., 1987), which also—because of its different
electrophoretic mobility—led to the suspicion that this NfH subunit
may not be expressed by this cell line at all (Lee, 1985). Consistent
with these data (Lee, 1985), others found phosphorylated NfH
levels to be barely detectable from PC12 cells (Dashiell et al.,
2002). In fact, the amount of NfH that we detected in PC12
Figure 6 Multimodal monitoring illustrates that extracellular ﬂuid NfH levels peaked in the acute phase of traumatic brain injury coin-
ciding with derangement of physiological parameters. The mode of injury in patients with traumatic brain injury was either due to a fall
(dotted line) or high-velocity impact traumatic brain injury (closed line). The multimodal data are plotted over time using 3h epochs.
(A) Extracellular ﬂuid NfH levels were signiﬁcantly higher in high impact traumatic brain injury compared with a fall (P50.0001). (B) The
extracellular ﬂuid lactate to pyruvate ratio was highest in high-velocity impact traumatic brain injury (P50.0001) suggesting critical
energy demand under anaerobic metabolic conditions. (C) The brain tissue oxygenation (BtO2) did not differ signiﬁcantly between groups.
(D) Initially the brain temperature (BT) was signiﬁcantly higher in high-velocity impact traumatic brain injury (P50.0001), but a crossover
of the curves occurred after six epochs, reﬂecting active cooling as part of intra-cranial pressure targeted management. (E) The systemic
oxygen saturation (SpO2) remained in the target range (498%) throughout and did not differ signiﬁcantly between the groups. (F) There
were no periods of systemic hypotension. The mean arterial blood pressure (ABP) increased to 480mmHg after nine epochs due to
volume resuscitation and inotropic support as part of targeted intra-cranial pressure management. (G) The mean intra-cranial pressure
(ICP) was signiﬁcantly higher after a fall (P50.0001) and continued to increase. The critical threshold of 20mmHg was passed after the
10th epoch. (H) Successful maintenance of the cerebral perfusion pressure (CPP) above 60mmHg was achieved by increasing the mean
arterial blood pressure until Epoch 15. From there on the continuous increase of intra-cranial pressure in patients with a fall started to
affect the cerebral perfusion pressure. The means   SD are shown.
Enterokinase neuroﬁlament cleavage in the brain Brain 2011: 134; 464–483 | 477Figure 7 Mechanisms leading to neuronal loss and increase of extracellular ﬂuid NfH. (A) The strength of signiﬁcant correlations
(Spearman’s R, y-axis) between extracellular ﬂuid NfH (eNfH) levels and physiological parameters during 3h epochs (x-axis) is shown. The
lactate to pyruvate ratio (LPR) is indicated by black bars, arterial blood pressure (ABP) by dark grey bars, cerebral perfusion pressure (CPP)
by light green bars, brain tissue oxygenation (BtO2) by hatched bars, brain temperature (BT) by blue bars. The grey box overlay highlights
the correlations for which the raw data are shown. (B) The lactate to pyruvate ratio correlated with extracellular ﬂuid NfH levels (Epoch 2).
(C) Because the lactate to pyruvate ratio increases under anaerobic metabolic conditions, this suggests that the resulting metabolic penalty
may cause neuronal loss with subsequent increase of extracellular ﬂuid NfH. (D) The mean arterial blood pressure correlated inversely with
extracellular ﬂuid NfH levels. (E) This raises the question whether ischaemic neuronal injury may be reduced by more aggressive arterial
blood pressure management. (F) The brain tissue oxygenation correlated with extracellular ﬂuid NfH levels. (G) This suggests that
increasing BtO2 may saturate systems of endogenous protection. The resulting O2 toxicity may cause neuronal injury resulting in increased
levels of extracellular ﬂuid NfH. (H) The brain temperature correlated with extracellular ﬂuid NfH levels. (I) This suggests that higher brain
temperature may accelerate mechanisms leading to neuronal apoptosis resulting in an increase of extracellular ﬂuid NfH levels.
ROS = reactive oxygen species, ***P50.0001, **P50.001, *P50.01,
†P50.05.
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which is 5–8 times less than what others found for tau protein
( 0.08% of total protein) or for microtubule associated protein 1
( 0.05% of total protein, after 3 days in culture, see Fig. 2 in
Drubin et al., 1985). This limitation prevents the use of NfH data
to estimate the absolute numbers of neurons lost in the human
brain, as the human neurons contain  24.6 times more NfH than
PC12 cells.
Testing our second research hypothesis, we found a relative
in vitro recovery of extracellular ﬂuid NfH of  20%. Thus the
relative recovery was substantially less than that of smaller com-
pounds such as pyruvate or lactate (Hutchinson et al., 2005;
Aﬁnowi et al., 2009), which may limit the quantiﬁcation of extra-
cellular ﬂuid NfH to scenarios involving a substantial degree of
neuronal and axonal loss. Substantial damage to the neurons
and their adjacent axons loss is seen in traumatic brain injury
(Gennarelli et al., 1982; Graham et al., 1992, 2005).
In line with the in vitro experiments, extracellular ﬂuid NfH was
detectable in vivo in patients with traumatic brain injury. It should
be noted that, in four patients, the concentration of extracellular
ﬂuid NfH measured in secondary peaks during the later disease
course exceeded that observed initially. This observation makes it
unlikely that extracellular ﬂuid NfH levels may be artefactually
high due to possible catheter insertion related parenchymal
damage (Bellander et al., 2004). Additionally, we strictly adhered
to consensus guidelines recommending a 1h catheter equilibration
period prior to analysis (Bellander et al., 2004). In one patient
(Patient 5), catheter insertion was delayed (5 days after impact),
therefore this patient may allow for a better distinction between
possible insertion artefact and traumatic brain injury-related injury.
The lactate and pyruvate data collected after insertion are in the
normal range and make an insertion artefact most unlikely
(Supplementary Fig. 1). In an additional post-mortem study and
consistent with the literature (Graham et al., 1992, 2005), we
demonstrated neuronal apoptosis in the cortex of patients with
traumatic brain injury. Neuronal apoptosis was identiﬁed using
caspase-3 immunostaining (Sulejczak et al., 2008; Sairanen
et al., 2009; Umschwief et al., 2010). There were essentially no
caspase-3 positive neurons in controls using either post-mortem
tissue or higher quality neurosurgical tissue from patients under-
going epilepsy surgery. Therefore, we interpret the initial extracel-
lular ﬂuid NfH peaks seen as evidence for primary neuronal injury
and the secondary peaks of neuronal damage due to secondary
brain damage. Taken together, the data provide in vivo evidence
that the major loss of cortical neurons and their adjacent axons
occurs in the acute phase after traumatic brain injury, possibly
related to shear forces and diffuse axonal injury (Gennarelli
et al., 1982).
The third research hypothesis tested in this study was inspired
by the observation that high-velocity impact traumatic brain injury
is associated with high mortality and morbidity ﬁgures (Adekoya
and Majumder, 2004; Walilko et al., 2005; Langlois et al., 2006b;
Minino et al., 2006). There is experimental and human
post-mortem evidence that high-velocity impact traumatic brain
injury is associated with substantial diffuse axonal injury and loss
of cortical neurons (Gennarelli et al., 1982; Graham et al., 1992,
2005; Hall et al., 2005; Deng et al., 2007). Due to small patient
numbers, the results of the present study need to be interpreted
with caution. The microdialysis in vivo data support the experi-
mental and post-mortem observations. The highest extracellular
ﬂuid NfH levels were found following high-velocity impact trau-
matic brain injury. This argument is further strengthened by a
body of literature describing widespread brain atrophy in traumatic
brain injury (reviewed in Levine et al., 2006). Longitudinal
Table 3 Physiological monitoring of hourly means
ID Hours of
recording
Time (%)
Intra-cranial
pressure
420 (%)
Cerebral perfusion
pressure 560 (%)
Lactate to
pyruvate ratio
425 (%)
Lactate to
pyruvate ratio
440 (%)
Brain tissue
oxygenation
535 (%)
Brain
temperature
438.1 (%)
18 9 1 7 8 7 9 0 6 5 0
2 102 62 17 5 1 99 0
3 50 70 46 91 0 92 0
4 353 20 15 12 1 73 27
5 174 0 4 53 25 93 87
6 48 8 19 71 3 93 0
7 31 16 3 42 0 97 44
8 110 46 18 0 0 4 30
9 32 6 41 93 7 NA 0
10 230 60 31 0 0 99 51
The percentage of hours with pathological values are shown. For the lactate to pyruvate ratio, two cut-off values are used i.e. 25 (published by Belli et al. 2008) and the
higher cut-off of 40 (published by Vespa et al. 2005). NA = not available.
Table 4 Odds ratio for predicting mortality in traumatic
brain injury
Marker ORs 95% CI P-value
Extracellular ﬂuid NfH 7.68 2.15–27.46 0.001
Intra-cranial pressure 5.06 1.84–13.89 0.001
GCS 4.13 1.72–9.94 0.001
Cerebral perfusion pressure 1.55 1.14–2.12 50.01
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volume may be lost following traumatic brain injury (Trivedi
et al., 2007). About 69% of the patients show an increase in
ventricular volume within 2 months of mild to moderate traumatic
brain injury (Poca et al., 2005). Moreover N-acetylaspartate, an-
other biomarker for neuronal loss, was found to decrease by
 12% in a traumatic brain injury cohort who suffered  1.09%
of total brain atrophy over one year (Cohen et al., 2007). An
important limitation not taken into account by our or any of the
cited studies is that the velocity of road trafﬁc accidents varies and
falls happen from different heights. Therefore combining patients
with road trafﬁc accidents and assault into one category
(high-velocity injury) is subject to criticism. Additional statistical
analyses splitting the patients into three different groups: road
trafﬁc accidents, assault and fall were in line with the results of
dichotomized groups. Again, numbers for these analyses were
even smaller, further decreasing the power of the study. A pos-
sible approach for future studies, to analyse the strength of impact
more accurately, could be to calculate the g–force (m/s) at impact
from an individual patient’s weight, the estimated road trafﬁc ac-
cident velocity and height of fall. There is increasing concern for
high-velocity injuries causing diffuse axonal injury in sport activities
(Gieron et al., 1998; Walilko et al., 2005), in road trafﬁc accidents
(Kirkpatrick, 1983; Corbo and Tripathi, 2004) and armed conﬂict
(Suneson et al., 1990; Bakir et al., 2005). The observation that
diffuse axonal injury may occur following high pressure waves
(Suneson et al., 1990) is interesting and could be further tested
using extracellular ﬂuid NfH as a biomarker.
The fourth hypothesis tested was that extracellular ﬂuid NfH
levels were related to the type of injury seen on CT brain imaging,
as suggested by the IMPACT studies (Steyerberg et al., 2008).
Higher extracellular ﬂuid NfH levels were found in the presence
of traumatic subarachnoid blood, but a confounding factor may be
that all of these patients died. The present study was underpow-
ered to allow for a multivariate analysis to exclude a possible bias
as recommended (Lingsma et al., 2010). For the same reason, one
would need to be careful to extrapolate from the absence of such
signiﬁcance based on either the Marshall classiﬁcation (Marshall
et al., 1992) or the presence or an extradural haematoma
(Steyerberg et al., 2008) from our data. Additionally the choice
to place the microdialysis catheter in the pericontusional tissue
meant that it was remote from the extradural haematoma in all
patients (see Patient 1, 8 and 9 in Fig. 5). Future studies investi-
gating a possible effect of extradural haematoma on the adjacent
brain tissue may be more informative if the microdialysis catheter
were placed adjacent to the extradural haematoma. For the pre-
sent study, diffuse axonal injury due to high-velocity injury seems
a more logical explanation for elevated extracellular ﬂuid NfH
levels.
The ﬁfth hypothesis tested was whether extracellular ﬂuid NfH
levels were correlated with physiological parameters that are
related to injury severity and outcome in traumatic brain injury.
For didactic reasons, the four parameters investigated are summar-
ized in Fig. 7C, E, G and I, adjacent to the raw data.
(i) Strong correlations were found between extracellular ﬂuid
NfH levels and the extracellular ﬂuid lactate to pyruvate
ratio. The data are consistent with observations suggesting
that an anaerobic metabolism/ischaemia causes an increase
in the lactate to pyruvate ratio (Enblad et al., 2001;
Hutchinson et al., 2002; Belli et al., 2008), and relates to
neuronal loss (Fig. 7C). However, it is still uncertain whether
this is an inexorable pathological cascade, as others have
found that a metabolic crisis can also occur without evidence
for ischaemic tissue damage (Vespa et al., 2005). We pro-
pose that extracellular ﬂuid NfH levels provide a sensitive
tool for investigating under which circumstances a high lac-
tate to pyruvate ratio may be related to neuronal loss
(Fig. 7C).
(ii) Correlations were found between extracellular ﬂuid NfH
levels and the systemic blood pressure. It is well established
that arterial blood pressure resuscitation is important to im-
prove outcome after traumatic brain injury (Butcher et al.,
2007; Stiver and Manley, 2008). Our ﬁndings raise the
question as to whether early and rigorous arterial blood
pressure resuscitation could reduce neuronal loss in trau-
matic brain injury. Extracellular ﬂuid NfH levels could be
used as a secondary outcome measure to test this hypoth-
esis (Fig. 7E).
(iii) Moderately strong correlations were found between extra-
cellular ﬂuid NfH levels and brain tissue oxygen levels. This
ﬁnding is in line with established experimental models show-
ing that oxygen toxicity results in neuronal loss (Arieli et al.,
2008). Experience in humans is possibly biased because most
data on oxygen toxicity come from prolonged hyperbaric
conditions during diving (Arieli et al., 2006). New data sug-
gest that short periods (1–2h) of normobaric hyperoxia may
improve the aerobic metabolism and cerebral blood ﬂow
(Shin et al., 2007; Nortje et al., 2008; Tisdall et al., 2008).
Additionally, there is considerable heterogeneity for cerebral
blood ﬂow and oxygen utilization between patients (Coles
et al., 2009). At present the routine clinical use of prolonged
hyperoxia is not recommended (Diringer, 2008), but extra-
cellular ﬂuid NfH levels offer a potential safety biomarker for
future trials investigating whether targeted short normobaric
hyperoxia may emerge as a neuroprotective treatment strat-
egy (Fig. 7G).
(iv) Finally extracellular ﬂuid NfH levels were related to the brain
temperature. Importantly, all correlations of brain tempera-
ture with extracellular ﬂuid NfH occurred in the acute phase
during which rapid hypothermia might have its strongest
neuroprotective mechanism (McIntyre et al., 2003;
Polderman, 2008; Bayir et al., 2009; Ma et al., 2009).
Extracellular ﬂuid NfH levels should be used as an exclusion
criteria and secondary outcome measure for future trials of
hypothermia in traumatic brain injury (Fig. 7I).
The sixth and the last hypothesis tested in this study was whether
extracellular ﬂuid NfH levels are of prognostic value after trau-
matic brain injury. We note that the mortality in our study is
higher than expected from other studies (Steyerberg et al.,
2008). This may in part be explained by the fact that initial
patient recruitment also included patients with traumatic brain
injury with milder injury (n = 5), but unfortunately a 20kDa
480 | Brain 2011: 134; 464–483 A. Petzold et al.microdialysis catheter was inserted and the collected extracellular
ﬂuid was, therefore, not suitable for the clinical part of this study.
In this small study, the proﬁle of extracellular ﬂuid NfH levels in
the initial 12h following traumatic brain injury predicted mortality
with an odds ratio of 7.68. The odds ratio for extracellular ﬂuid
NfH levels compared favourably to the Glasgow Coma Score
(GCS, odds ratio 4.13) and other clinical predictors derived from
the large IMPACT data set on 8509 patients with traumatic brain
injury (motor score of the GCS 1.0–5.7) (Steyerberg et al., 2008).
In conclusion, this translational proof of principle study describes
a novel neuronal proteolytic pathway responsible for the release of
a speciﬁc protein biomarker into the human extracellular ﬂuid.
Quantiﬁcation of this biomarker—extracellular ﬂuid NfH—seems
feasible, allowing for in vivo monitoring of neurodegeneration in
traumatic brain injury. The limited number of cases in this study
prevents generalization from our data. The in vivo data support
experimental, post-mortem and imaging data, suggesting that
neuronal loss is likely to be most extensive following high-velocity
impact traumatic brain injury. The data also suggest that extra-
cellular ﬂuid NfH levels may be a useful biomarker in this context
and might predict poor functional outcome.
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